|
1. Biologie
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Doctor and dad duo design new 'cancer maps' to aid diagnosis [Cancer Research UK]
|
|
|
|
|
|
The
innovative ‘Cancer Maps’ were developed to help make it easier for GPs
to navigate the cancer recognition and referral guidelines published by
the National Institute for Health and Care Excellence (NICE) in 2015. Dr
Noble’s brainchild has so impressed the medical community that it has
been endorsed by NICE and the Royal College of GPs and will soon be
rolled out across the UK.
|
|
|
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5. Traitements
|
|
|
Oncology in Transition - Changes, Challenges, and Opportunities [JAMA]
|
|
|
|
|
|
The
series of Viewpoints, which begins in this issue of JAMA, will include
thought leaders from academia, patient advocacy, industry, and
government along with basic, translational, clinical, and population
scientists. Its purpose is to provide JAMA readers with perspective on
the challenges ahead.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.12.9 Immunothérapies - SITC
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
EMA’s Regulatory Science Strategy to 2025 [ESMO]
|
|
|
|
|
|
The
workshop offered an opportunity to reflect on the scientific and
technological advances in the pharmaceutical arena, the challenges that
the Agency’s scientific committees and working parties will face in the
future and to look at initial proposals to address them.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
NICE nod for Jazz’ AML chemo [PharmaTimes]
|
|
|
|
|
|
Jazz
Pharmaceuticals has revealed that NICE has chosen to recommend that its
44mg/100mg powder formulation of Vyxeos for concentrate for solution
for infusion be adopted by the NHS for regular use, bringing the first
new chemotherapy drug for the treatment of two types of secondary acute
myeloid leukaemia (AML) in 40 years.
|
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.12 Ethique
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
6.8 Communication
|
|
|